戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  points included the incidence of ocular and nonocular adverse events (AEs) and AEs of special intere
2 es were incidence and severity of ocular and nonocular adverse events (AEs).
3 were observed in the incidence of ocular and nonocular adverse events or events of interest.
4 ty statistics, the frequencies of ocular and nonocular adverse events seemed to be slightly higher am
5                                           No nonocular adverse events were considered related to stud
6                                   No serious nonocular adverse events were reported.
7  The primary safety measures were ocular and nonocular adverse events.
8 ty measures were local (ocular) or systemic (nonocular) adverse events (AEs) during the 12-month peri
9                                              Nonocular AEs included cardiac AEs (n = 3, 4 events), py
10                                         Main nonocular AEs were hypertension and nasopharyngitis (9.0
11                                     The main nonocular AEs were nasopharyngitis (18.8%) and hypertens
12    Study eye ocular adverse events (AEs) and nonocular AEs were similar between treatment groups.
13 ic metastatic disease, then treatment of the nonocular and ocular metastatic tumors consists of chemo
14 reported, with 93% described as mild, 95% as nonocular, and only 14% deemed possibly caused by the in
15 s with TCF8 mutations should be examined for nonocular anomalies.
16  may be more effective for rheumatologic and nonocular autoimmune disorders than for uveitis.
17 upports current standard of care to pursue a nonocular biopsy of normal-appearing, perilesional skin
18  imaging uncovered previously occult primary nonocular cancers (11/18, 61%), revealed progression of
19 reports, involving some types of autologous, nonocular cell sources, have been linked to severe, blin
20 ial cells, although receptors on a few other nonocular cell types also have been described.
21      Severity of ocular pain correlates with nonocular comorbidities such as use of antidepressant me
22 ntified sociodemographic factors, ocular and nonocular conditions associated with incident BRVO.
23          PET/CT findings were used to direct nonocular, confirmatory biopsy in 67% of cases (12/18).
24 esent with an ocular diagnosis compared to a nonocular diagnosis (odds ratio [OR]: 2.64; 95% confiden
25 ovative therapies for a myriad of ocular and nonocular diseases characterized by pathologic angiogene
26  role in the pathogenesis of many ocular and nonocular diseases, such as age-related macular degenera
27 er factor, stimulates growth and motility in nonocular endothelial cells and smooth muscle cells thro
28 erious ocular adverse events and few serious nonocular events; none was judged as associated with atr
29 bizumab therapy in DME was not influenced by nonocular factors related to systemic management of diab
30                                          The nonocular features included white forelock in 4 of 7 (57
31 l 9 had abusive head trauma diagnosable with nonocular findings.
32 ients with DME, with low rates of ocular and nonocular harm.
33 ion of anti-VEGF drugs increased the risk of nonocular hemorrhage (OR, 1.46; 95% CI, 1.01-2.10), main
34                  Secondary outcomes included nonocular hemorrhage, components of MACEs, other cardiov
35 ased mortality in patients with diabetes and nonocular hemorrhages, especially in those with AMD, cou
36 ular events (OR, 1.18; 95% CI, 0.81-1.71) or nonocular hemorrhagic events (OR, 1.42; 95% CI, 0.95-2.1
37 ular events (OR, 0.94; 95% CI, 0.59-1.52) or nonocular hemorrhagic events (OR, 2.56; 95% CI, 0.78-8.3
38 Increased risks of VTEs with bevacizumab and nonocular hemorrhagic events in older patients with AMD
39 up analysis showed a significant increase of nonocular hemorrhagic events in patients with AMD in ran
40 ificant increases in major cardiovascular or nonocular hemorrhagic events, but studies and meta-analy
41 ary end points were major cardiovascular and nonocular hemorrhagic events.
42 keratitis (HSK) were compared with sera from nonocular HSV-1-seropositive and HSV-seronegative contro
43 ma suspect, ocular hypertension, or non-POAG/nonocular hypertension.
44  of VCPs), but other ocular test results and nonocular information were infrequently obtained.
45 ve munitions cause high rates of concomitant nonocular injuries such as traumatic brain injury, amput
46 ched more than fivefold over other published nonocular libraries.
47                        By contrast, for DIF+ nonocular MMP patients, all the individual tests, apart
48 the retinal vasculature, retina, and several nonocular organs (lungs, liver, and spleen).
49 sttraumatic stress disorder and depression), nonocular pain, and medications (eg, anxiolytics and ana
50 nally, such as psychiatric comorbidities and nonocular pain, were also associated with severe dry eye
51  Pseudomonas aeruginosa was expressed in the nonocular pathogenic host, Pseudomonas putida, to elucid
52                            All patients with nonocular phenotypic abnormalities had detectable mutati
53 A) probands, including five with additional, nonocular phenotypic abnormalities.
54 stmenstrual age at treatment, and coincident nonocular procedures during anesthesia.
55                                              Nonocular risk factors included sleep disturbances (eg,
56                                 Furthermore, nonocular risk factors that have been associated with dr
57                             The incidence of nonocular SAEs was 8.8% in the IAI group and 9.8% in the
58 es of endophthalmitis, and the incidences of nonocular SAEs were low.
59                             No new ocular or nonocular safety events were observed.
60                  There were no new ocular or nonocular safety events.
61                             No new ocular or nonocular safety findings were observed during the study
62 parison of these libraries with 100 reported nonocular SAGE libraries revealed 89 retina-specific or
63                                Incidences of nonocular serious AEs generally were well balanced betwe
64 tudy the effects of CsA on angiogenesis in a nonocular site.
65 cle, iris, ciliary body, cornea, and several nonocular sites, such as heart and nasal epithelium.
66 GM1 eliminated NK activity in the eye and at nonocular sites.
67  and biochemically unique when compared with nonocular skeletal muscles.
68 during the treatment period; most were mild, nonocular (sneezing, cough, throat irritation, and insti
69 nsistent with resistance trends reported for nonocular staphylococcal isolates.
70 t common ocular complication associated with nonocular surgery, but toxic keratopathy is rare.
71 n association of exfoliation syndrome with a nonocular systemic condition.
72 ure to dexamethasone after iontophoresis; no nonocular systemic corticosteroid-mediated effects were
73                                           In nonocular systems, activation of opioid receptors has be
74 y alter vascular permeability in a number of nonocular tissues via Src kinase-regulated signaling pat
75                           Retinoid levels in nonocular tissues were also analyzed for comparison.
76 vascular hyperpermeability in all ocular and nonocular tissues, prevented the increase in vascular co
77 h myocilin is detected in several ocular and nonocular tissues, the only reported human pathology rel
78 ppress TGF-beta-induced fibrogenesis in many nonocular tissues.
79  levels were higher in mouse eyecups than in nonocular tissues.
80  be less than if transplanted cells are from nonocular tissues.
81 t, and prevention of apoptotic cell death in nonocular tissues.
82 ation and a known vasopermeability factor in nonocular tissues.
83 ve immune response both in ocular as well as nonocular tissues.
84 elationship between ICP and other ocular and nonocular variables was performed by using univariate an